Orion Oyj (OTCMKTS:ORINY) Sees Large Decrease in Short Interest

Orion Oyj (OTCMKTS:ORINY) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 400 shares, a drop of 92.0% from the March 31st total of 5,000 shares. Based on an average daily trading volume, of 7,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Nordea Equity Research lowered Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

Orion Oyj Trading Up 3.8 %

Shares of ORINY opened at $30.63 on Monday. Orion Oyj has a 1-year low of $19.97 and a 1-year high of $31.10. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The firm’s 50-day moving average price is $28.80 and its 200-day moving average price is $25.86. The firm has a market capitalization of $8.65 billion, a price-to-earnings ratio of 24.31 and a beta of 0.15.

Orion Oyj (OTCMKTS:ORINY) last posted its earnings results on Wednesday, April 23rd. The company reported $0.23 earnings per share for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The firm had revenue of $373.03 million for the quarter. Sell-side analysts anticipate that Orion Oyj will post 1.18 EPS for the current year.

Orion Oyj Increases Dividend

The company also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th will be given a dividend of $0.4478 per share. The ex-dividend date of this dividend is Monday, April 7th. This is a positive change from Orion Oyj’s previous dividend of $0.24. Orion Oyj’s dividend payout ratio (DPR) is currently 24.43%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.